Immunological origin and functional properties of catalytic autoantibodies to amyloid β peptide

Journal of Clinical Immunology

Volumn 30, Issue SUPPL. 1, 2010, Pages

  Paul, Sudhir ^a   Planque, Stephanie ^a   Nishiyama, Yasuhiro ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Amyloid peptide; Catalytic antibody; Immunotherapy

Indexed keywords

AMYLOID BETA PROTEIN; AUTOANTIBODY; BAPINEUZUMAB; CARIMUNE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTRATECT; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIGEN; CATALYTIC ANTIBODY; PEPTIDE FRAGMENT;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD ANALYSIS; CATALYSIS; CLINICAL TRIAL; CYTOTOXICITY; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG SAFETY; GENE OVEREXPRESSION; HUMAN; IMMUNOTHERAPY; INNATE IMMUNITY; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; PROTEIN ISOLATION; TISSUE CULTURE; BIOLOGICAL MODEL; HYDROLYSIS; IMMUNOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIBODIES, CATALYTIC; AUTOANTIBODIES; AUTOANTIGENS; HUMANS; HYDROLYSIS; IMMUNITY, INNATE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; MODELS, IMMUNOLOGICAL; PEPTIDE FRAGMENTS; AMYLOID BETA-PEPTIDES;

EID: 77956188133     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-010-9414-5     Document Type: Article

References (28)

1. Vani J, Elluru S, Negi VS, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev. 2008;7:440-444
2. Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science. 1989;244:1158-1162
3. Paul S, Nishiyama Y, Planque S, Taguchi H. Theory of proteolytic antibody occurrence. Immunol Lett. 2006;103:8-16.
4. Paul S, Nishiyama Y, Planque S, Karle S, Taguchi H, Hanson C, et al. Antibodies as defensive enzymes. Springer Semin Immunopathol. 2005;26:485-503.
5. Planque S, Mitsuda Y, Taguchi H, Salas M, Morris MK, Nishiyama Y, et al. Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infection. AIDS Res Hum Retroviruses. 2007;23:1541-1554
6. Walsh DM, Selkoe DJ. Aβ oligomers-a decade of discovery. J Neurochem. 2007;101:1172-1184
7. Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci. 2008; 31:175-193
8. Szabo P, Relkin N, Weksler ME. Natural human antibodies to amyloid β peptide. Autoimmun Rev. 2008;7:415-420
9. O'Nuallain B, Acero L, Williams AD, Koeppen HP, Weber A, Schwarz HP, et al. Human plasma contains cross-reactive Aβ conformer-specific IgG antibodies. Biochemistry. 2008; 47:12254-12256
10. Taguchi H, Planque S, Nishiyama Y, Szabo P, Weksler ME, Friedland RP, et al. Catalytic antibodies to amyloid β peptide in defense against Alzheimer's disease. Autoimmun Rev. 2008;7:391-397
11. Taguchi H, Planque S, Nishiyama Y, Symersky J, Boivin S, Szabo P, et al. Autoantibody-catalyzed hydrolysis of amyloid β peptide. J Biol Chem. 2008;283:4714-4722
12. Qahwash IM, Boire A, Lanning J, Krausz T, Pytel P, Meredith SC. Site-specific effects of peptide lipidation on β-amyloid aggregation and cytotoxicity. J Biol Chem. 2007;282:36987-36997
13. Munch G, Mayer S, Michaelis J, Hipkiss AR, Riederer P, Muller R, et al. Influence of advanced glycation end-products and AGEinhibitors on nucleation-dependent polymerization of β-amyloid peptide. Biochim Biophys Acta. 1997;1360:17-29.
14. Adekar SP, Klyubin I, Macy S, Rowan MJ, Solomon A, Dessain SK, et al. Inherent anti-amyloidogenic activity of human Ig ? heavy chains. J Biol Chem. 2009. doi:10.1074/jbc.M109.044321.
15. Silverman GJ, Goodyear CS. Confounding B-cell defenses: lessons from a staphylococcal superantigen. Nat Rev Immunol. 2006;6:465-475
16. Paul S, Planque S, Zhou YX, Taguchi H, Bhatia G, Karle S, et al. Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J Biol Chem. 2003;278:20429-20435
17. Durova OM, Vorobiev II, Smirnov IV, Reshetnyak AV, Telegin GB, Shamborant OG, et al. Strategies for induction of catalytic antibodies toward HIV-1 glycoprotein gp120 in autoimmune prone mice. Mol Immunol. 2009;47:87-95.
18. Li Q, Gordon M, Cao C, Ugen K, Morgan D. Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Aβ antibodies. BMC Neurosci. 2007;8:22.
19. Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Zamrini EY, et al. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Aβ and RAGE peptides. Neurobiol Aging. 2004;25:1023-1032
20. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer's disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol. 2002;37:943-948
21. Istrin G, Bosis E, Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res. 2006;84:434-443
22. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer's disease. Neurobiol Aging. 2009;30:1728-1736
23. Bacher M, Depboylu C, Du Y, Noelker C, Oertel WH, Behr T, et al. Peripheral and central biodistribution of (111)In-labeled anti-β- amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. Neurosci Lett. 2009;449:240-245
24. Mitsuda Y, Planque S, Hara M, Kyle R, Taguchi H, Nishiyama Y, et al. Naturally occurring catalytic antibodies: evidence for preferred development of the catalytic function in IgA class antibodies. Mol Biotechnol. 2007;36:113-122
25. Taguchi H, Planque S, Sapparapu G, Boivin S, Hara M, Nishiyama Y, et al. Exceptional amyloid β peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds. J Biol Chem. 2008;283:36724-36733
26. St-Amour I, Laroche A, Bazin R, Lemieux R. Activation of cryptic IgG reactive with BAFF, amyloid β peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins. Clin Immunol. 2009;133:52-60.
27. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27:9115-9129
28. Lacroix-Desmazes S, Bayry J, Kaveri SV, Hayon-Sonsino D, Thorenoor N, Charpentier J, et al. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc Natl Acad Sci USA. 2005;102:4109-4113